Excess visceral fat leads to increased production of pro-inflammatory cytokines, including TNF-, IL-6, and IL-17, as well as the following adipokines: leptin, visfatin, and resistin, which exacerbate inflammation (205)
[2] Beyond skin: pulmonary fibrosis
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
Suitable for: Individuals who want to rejuvenate their body, enhance physical and mental performance, improve nutrient levels, or experience fatigue, weakness, stress, or insufficient rest